Results 101 to 110 of about 726,956 (307)

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

Molecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman   +17 more
wiley   +1 more source

Measuring irritable bowel syndrome patient‐reported outcomes with an abdominal pain numeric rating scale [PDF]

, 2009
Brennan Spiegel, Roger Bolus, Lucinda A. Harris, Susan Lucak, Bruce D. Naliboff, Eric Esrailian, William D. Chey, Anthony Lembo, Hetal A. Karsan, Kirsten Tillisch, Jennifer Talley, Emeran A. Mayer, Lin Chang   +12 more
openalex   +1 more source

Dose‐dependent induction of epithelial‐mesenchymal transition in 3D melanoma models by non‐thermal plasma treatment

Molecular Oncology, EarlyView.
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop, Edgar Cardenas De La Hoz, Hanne Verswyvel, Joey De Backer, Ho Wa Lau, Angela Privat‐Maldonado, Wim Vanden Berghe, Steve Vanlanduit, Evelien Smits, Annemie Bogaerts, Abraham Lin   +10 more
wiley   +1 more source

Educating patients about patient-reported outcomes—are we there yet?

Journal of Patient-Reported Outcomes
Background Using Patient Reported Outcome Measures (PROMs) in clinical settings can improve patient outcomes by enhancing communication between patient and provider.
Elizabeth Unni, Maud M. van Muilekom, Kate Absolom, Bishnu Bajgain, Lotte Haverman, Maria Santana   +5 more
doaj   +1 more source

Measuring patients' views: a bifactor model of distinct patient-reported outcomes in psychosis [PDF]

, 2010
Ulrich Reininghaus, Rose McCabe, Tom Burns, Tim Croudace, Stefan Priebe   +4 more
openalex   +1 more source

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

Molecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom   +8 more
wiley   +1 more source

Patient-Reported Outcomes in Integrated Care: A Frontier of Opportunities and Challenges

International Journal of Integrated Care
Effective care integration requires the right information, at the right time, with care and support delivered in the right environment. Patient-reported outcome measures [PROMs] offer a mechanism to support collaborative integrated care to help people ...
Nicola Anderson, Sarah E. Hughes, Olalekan L. Aiyegbusi, Philip Collis, Robin Miller, Melanie Calvert   +5 more
doaj   +1 more source

Development and Validation of Patient-Reported Outcome Measures for Sleep Disturbance and Sleep-Related Impairments [PDF]

, 2010
Daniel J. Buysse, Lan Yu, Douglas E. Moul, Anne Germain, Angela M. Stover, Nathan E. Dodds, Kelly L. Johnston, Melissa A. Shablesky-Cade, Paul A. Pilkonis   +8 more
openalex   +1 more source

Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma

Molecular Oncology, EarlyView.
GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski, Molly R. Danks, John P. Thomson, Morwenna Muir, Martin Lee, John C. Dawson, Ana T. Amaral, Juan Diaz‐Martin, David S. Moura, Javier Martin‐Broto, Ali Alsaadi, Donald M. Salter, Ailsa J. Oswald, Graeme Grimes, Larry Hayward, Ted R. Hupp, Karen Sisley, Paul H. Huang, Neil O. Carragher, Valerie G. Brunton   +19 more
wiley   +1 more source

Evaluation of Ankylosing Spondylitis Quality of Life (EASi-QoL): Reliability and Validity of a New Patient-reported Outcome Measure [PDF]

, 2010
Kirstie Haywood, Andrew Garratt, Kelvin P. Jordan, Emma L. Healey, Jon Packham   +4 more
openalex   +1 more source